Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

What is choroideremia?

Choroideremia is an incurable genetic disease that causes blindness in men, and affects approximately one in 50,000 people. The disease is caused by a defect in the CHM gene which is located on the X-chromosome, and this is why the disease affects men and women differently. Women have two X-chromosomes and so a normal CHM gene on one X-chromosome can compensate for a defective CHM gene on the other X-chromosome to some extent. Men, however, only have one X-chromosome.

The CHM gene encodes a special protein called Rab-escort protein 1 (REP1) which plays a key role in the metabolism of the cells making up the retina, which is the light-sensitive layer (like a camera film) that lines the back of the eye. The absence of REP1 in the retinal cells causes them to die over time, resulting in a progressive degeneration of the retina and consequent loss of vision. Sight loss in choroideremia begins with ‘night blindness’ (i.e. loss of night vision) in adolescence, followed by a gradual loss of peripheral vision which results in progressively worsening ‘tunnel vision’.  Ultimately, central vision is lost by the fourth or fifth decade.

Gene therapy for choroideremia

There are currently no effective treatments available for choroideremia, but we have developed a new technique of gene therapy which we believe may help to slow or even stop the degeneration. The new technique involves putting normal copies of the affected gene back into the cells of the retina to help them to function normally. In order to do this, we need to use a vector (i.e. carrier) of the normal gene that can safely bring the normal genes back into the retinal cells without harming them.

The vector that we use is a small virus known as adeno-associated virus (AAV), which is non-pathogenic (i.e. not known to cause disease). AAV serotype 2 (AAV2) is notably effective at getting into retinal cells, and so this particular strain of AAV strain is used as the vector for our REP1 gene replacement therapy.

In order to administer our gene therapy vector, known as AAV2.REP1, the eye's clear internal jelly must first be removed by a type of 'key-hole' surgery known as a vitrectomy. This procedure is quite safe, and the eye's clear internal jelly is gradually restored by the body in the weeks following the surgery.

After the vitrectomy, a small volume of fluid containing the AAV2.REP1 vector is injected underneath the retina through a very fine needle that is narrower than a human hair, creating a small fluid-filled blister or bleb under the retina. This small area of retinal detachment is temporary and disappears over about 24 hours as the fluid gets slowly absorbed by the retina. This type of surgery normally lasts about an hour, and the operation itself (without the gene therapy) is a routine procedure for patients with conditions such as retinal detachment. 

Phase 1/2 clinical trial

Choroideremia Gene TherapyOn 24 November 2011, Jonathan Wyatt became the first person in the world to receive the gene therapy for choroideremia in an operation conducted at the John Radcliffe Hospital in Oxford and led by Professor Robert MacLaren.

This Phase 1/2 clinical trial was designed to test the safety and efficacy of the choroideremia gene therapy at two doses of viral vector (low and standard). The initial findings were published in The Lancet and the New England Journal of Medicine. A total of 14 choroideremia patients were treated - 6 with the low dose vector and 8 with the standard dose vector.

Phase 2 clinical trial

OCT MicroscopeOn the 1 September 2016, Paul McGuire became the first patient be treated in the Phase 2 clinical trial, in an operation conducted at the John Radcliffe Hospital in Oxford and led by Professor Robert MacLaren. Paul McGuire also became the first patient in the UK to undergo gene therapy surgery using an operating microscope with integrated optical coherence tomography (OCT). This state-of-the-art operating microscope has a built-in OCT scanner which uses a laser to define the retinal layers, and these are projected into the microscope field through an internal image similar to a head-up display – enabling a vitreoretinal surgeon to see a cross-sectional scan of the retina in real time during a surgical procedure. The use of intraoperative OCT enables surgeons to track changes in retinal anatomy in real time and thereby permit very delicate or highly complex surgical operations to be conducted with an unprecedented level of precision.

A total of 30 patients will be treated with the standard dose of viral vector in the Phase 2 clinical trial, which is known as the REGENERATE (REP1 Gene Replacement Therapy) study. The REGENERATE study is ongoing, with patients being treated at the John Radcliffe Hospital in Oxford and the Moorfields Eye Hospital in London.